Response to AREDS formulation depends on genotype

CHICAGO – The response to AREDS supplementation in patients with age-related macular degeneration varies greatly based on CFH and ARMS2 risk, according to a speaker here.In a statistical genetic analysis published in Ophthalmology, Carl C. Awh, MD, and colleagues delineated risk of AMD progression in genotype subgroups culled from the AREDS cohort.